Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease Abbott announced excellent results from a Stage 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to greatly help slow chronic kidney disease progression in patients with type 2 diabetic nephropathy . Study results suggest that atrasentan, used in conjunction with renin-angiotensin program inhibitors, may decrease albuminuria for sufferers with type 2 diabetes. Albuminuria is the main indication of diabetic nephropathy and as kidney function decreases, the amount of albumin in the urine rises inhisimagefamilymedicine.com . Results were offered at the annual American Culture of Nephrology conference in Denver, Colorado.
White colored, chairman and chief executive officer, Abbott. Piramal’s portfolio of well-known, trusted items has served patients in India for decades. Combined with existing item offerings, Abbott is usually uniquely positioned to meet the needs of 1 of the world’s fastest-growing pharmaceutical markets. India’s rapid pharmaceutical marketplace growth is being driven largely by top quality generics. The market will generate nearly $8 billion in pharmaceutical sales this year, a true number that’s expected to a lot more than double by 2015. Abbott expects its pharmaceutical product sales in India to surpass $2.5 billion by 2020. Piramal’s Healthcare Solutions business has a extensive portfolio of top quality generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience.